Clinical Trial Data Management

During the last 3 decades the Clinical Research Organisation industry has evolved from a few small industrial providers offering a pressure valve to the pharmaceutical industry to a well recognised multi billion industry, growing by 10-15% once a year and utilising in the region of 100,000 specialists in most of Clinical Research Organisations globally.

There has been a proliferation of companies, amalgamations and acquisitions which has guided to the formation of some very large multinational companies utilisaing as many as 15,000 employess worldwide. However, the market place is as diverse and as open for new missions as it has been for decades; just very larger in size.

Unfortunately, one of the biggest drivers for the growth of this industry has been the ever growing rigid requirements rather than an increase in true innovation. Yet new approaches in drug development such as personalised medicines and the progression of biological medicines will undoubtedly evolve the face of this industry. It is likely to continue to flourish but more in terms of size and diversity.

Entering uncharted regions is the foundation of all research and as such needs a constantly broadening range of professionals who can add to the new challenges within clinical research.

The industry has seen partnerships evolve. Whilst other industries have embraced this concept it has not really materialised in the pharmaceutical research market.The processes by which clinical trial services are purchased have become smarter and more structured. The demand for standardised procedures dealing with large amounts of tests and data in some areas of full drug development have created a massive demand and the subsequent formation of large and process driven CROs frequently supplying the main pharmaceutical organisations. However, large processing units are not the most suitable environments for real innovation and it is not surprising that formidable pharmaceutical organisations constantly look for new alliances in the biotech and CRO industry.

Improvements is the key of excellence usually delivered by an individual. However, large development programmes are reliant on large infrastructures. These are very different needs that the industry has and it is unlikely that they will ever be efficiently met by any one CRO company.

However large the portfolio of a CRO may be, the forte of any large organisation is the ability to process large amounts of goods or clinical data management in a uniform way. The advantage of smaller companies is their ability to adapt to new challenges quickly and deliver true innovation. It follows that the diversity we currently see in the CRO market place is likely to continue providing the opportunities for new entrants to the market|However big the Clinical Research Industry is, the strong point of any formidable company is to have consistency with processing large amounts of products, services or data .

The increasing numbers of patients needed for trials, does require reassurances to the public with regard to the safety of those Clinical trials UK. The number of regulations is likely to increase which will in turn create an increase in bureaucracy. This again will create a demand for larger organisations to process large amounts of data creating very large databases. Yet more regulations do not necessarily make research safer as the recent unprecedented tragedy at Northwick Park Hospital in London has shown. In this instance all relevant regulations were followed yet the information available was not evaluated in the appropriate way and as a consequence a far too high dose was given to a group of six previously healthy volunteers.  The challenge in controlling such complex issues is to find and involve a highly specialised expert in a particular field and to ensure that all available data is evaluated appropriately in the approval process. This represents a challenge, and in this instance, again, size will not be the answer.

Innovation and research require a large arsenal of research tools and services as well as an effectively functioning network, facilitating the access to and exchange of information, both on available services and expertise. It is the creation of these knowledge based networks which will create the most exciting opportunities for the future of a diverse and thriving Clinical Research market.

Blogging

Related posts:

1. Safeguarding Essential Docs By Means Of Utilizing Data Encryption Technique Information thievery is the main explanation why individuals are not...
2. Tahitian Noni is validate by science, 14 clinical human studies completed Ever wondered why the first a couple of ingredients of...
3. Euro Drops on Low Consumer Confidence Data and Ongoing Debt Problems The dollar rallied in recent trading activity as strong U.S....
4. IRM – Internet Reputation Management   Is your reputation is being attacked on the Internet,...
5. Through the Looking Glass: Virtualisation, Adaptability and Data Security Your business IT requirements are, at foundation level, two fold....